Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types.
Learn about the mechanism of action of ADCs, the key clinical trials in the breast and lung cancer settings, as well as current challenges and future directions in this expert-led symposium.
You must have an account and be logged in to access the recording of this webinar. The on-demand version is not accredited.
Personal financial interests: None (since August 2021)
Institutional financial interests: Abbvie, ACEA, Amgen, Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis and Takeda
Non-financial interests: Principal Investigator for Astra-Zeneca, BMS, Innate Pharma, Merck, Mirati, Pierre Fabre and F. Hoffmann-La Roche, Ltd, sponsored trials (or ISR)
Moderators
Dr. Shreeya Nanda
Senior Clinical Content Manager, Springer Medicine, London, UK